{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Vanda Pharmaceuticals, Inc.
Vanda Pharmaceuticals Hits New 52-Week High of $5.59
Vanda Pharmaceuticals, Inc. achieved a new 52-week high of USD 5.59 on October 8, 2025, despite a 1-year performance decline of 8.7%. The company, with a market capitalization of USD 269 million, remains loss-making and does not offer a dividend yield, reflecting its growth stage in the pharmaceuticals industry.
Vanda Pharmaceuticals Forms Golden Cross, Signaling Potential Bullish Breakout
Vanda Pharmaceuticals, Inc. has recently achieved a Golden Cross, indicating a potential shift in market sentiment. The stock has shown strong daily and weekly performance, outperforming the S&P 500. Despite past declines over three and five years, recent bullish indicators suggest renewed investor interest in the company.
Vanda Pharmaceuticals Forms Death Cross, Signaling Potential Bearish Trend Ahead
Vanda Pharmaceuticals has recently encountered a Death Cross, indicating a potential shift in market sentiment. Technical indicators present a mixed outlook, with some showing bullish momentum while others suggest short-term challenges. Over the long term, the company has underperformed significantly compared to the S&P 500, raising investor concerns.
Is Vanda Pharmaceuticals, Inc. technically bullish or bearish?
As of September 11, 2025, Vanda Pharmaceuticals' technical trend is neutral with mixed signals, showing a mildly bullish MACD but overall underperformance compared to the S&P 500, with year-to-date returns of -5.64% versus 12.22% for the index.
Is Vanda Pharmaceuticals, Inc. overvalued or undervalued?
As of May 8, 2024, Vanda Pharmaceuticals is considered overvalued and has been downgraded to a risky valuation grade, with poor financial metrics and significant underperformance compared to the S&P 500.
Is Vanda Pharmaceuticals, Inc. overvalued or undervalued?
As of May 8, 2024, Vanda Pharmaceuticals is considered overvalued and risky, with unfavorable financial metrics including a price-to-book ratio of 0.53, an EV to EBITDA ratio of 1.00, and a negative return on equity of -8.65%, significantly underperforming compared to its peers and the S&P 500.
Is Vanda Pharmaceuticals, Inc. technically bullish or bearish?
As of June 11, 2025, Vanda Pharmaceuticals, Inc. shows a mildly bearish trend, influenced by daily moving averages and tempered by Bollinger Bands and Dow Theory, despite some bullish indicators on the weekly and monthly MACD and KST.
Who are in the management team of Vanda Pharmaceuticals, Inc.?
As of March 2022, Vanda Pharmaceuticals, Inc.'s management team includes H. Thomas Watkins (Independent Chairman), Dr. Mihael Polymeropoulos (President and CEO), and several Independent Directors: Phaedra Chrousos, Richard Dugan, Stephen Mitchell, and Anne Ward. The team features a blend of executive leadership and independent governance.
What does Vanda Pharmaceuticals, Inc. do?
Vanda Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapies for unmet medical needs. As of March 2025, it reported net sales of $50 million and a net loss of $29 million, with a market cap of $264.62 million.
How big is Vanda Pharmaceuticals, Inc.?
As of Jun 18, Vanda Pharmaceuticals, Inc. has a market capitalization of 264.62 million and reported net sales of 201.35 million with a net profit of -44.24 million over the latest four quarters. Shareholder's funds are 538.55 million, and total assets amount to 656.20 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
